Servicio de Información Comunitario sobre Investigación y Desarrollo - CORDIS

FP5

IMPALED Informe resumido

Project ID: QLK3-CT-2002-01956
Financiado con arreglo a: FP5-LIFE QUALITY
País: Sweden

Mechanism of tumour sensitivity to novel DNA damaging drugs

We have developed a novel series of DNA reactive peptides (DR peptides) that carry groups which alkylate DNA and as such resemble conventional alkylating agents i.e. Melphalan.

Our lead DR peptides do, however, circumvent resistance to conventional alkylating agents and in this work we have explored mechanisms behind the efficacy of DR peptides in tumour cell lines.

Moreover, we have studied which combinations of DR peptides and chemotherapy agents that have synergistic effects when used in combination.

In addition, a candidate drug is now underway to formal pre-IND testing. Results show that DR peptides have improved efficiency compared to the lead substance Melfalan in several human tumours cell lines including lines derived from lung cancer.

A synergistic effect between DR peptides and DNA damaging therapy e.g., topo II inhibitors, cyclophosphamide and carboplatin in childhood tumour neuroblastoma.

Our data show that lysosomes are involved in DR peptide induced cell death in tumour cell lines as are stress activated protein kinases. Potential users of this knowledge are pharmaceutical industries developing DNA damaging sensitizing drugs and researchers, which analyze chemoresistance mechanisms.

Información relacionada

Contacto

Rolf LEWENSOHN, (Research Director)
Tel.: +46-851773188
Fax: +46-851775042
Correo electrónico
Síganos en: RSS Facebook Twitter YouTube Gestionado por la Oficina de Publicaciones de la UE Arriba